Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Summit Therapeutics Inc (NASDAQ: SMMT) closed at $23.84 up 0.59% from its previous closing price of $23.7. In other words, the price has increased by $0.59 from its previous closing price. On the day, 1.81 million shares were traded. SMMT stock price reached its highest trading level at $24.2 during the session, while it also had its lowest trading level at $23.09.
Ratios:
For a deeper understanding of Summit Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.13 and its Current Ratio is at 5.13. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Neutral rating and assigned the stock a target price of $21.
On July 01, 2025, UBS started tracking the stock assigning a Buy rating and target price of $30. On June 11, 2025, Leerink Partners started tracking the stock assigning a Underperform rating and target price of $12.Leerink Partners initiated its Underperform rating on June 11, 2025, with a $12 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SMMT now has a Market Capitalization of 17709471744 and an Enterprise Value of 17417146368.
Stock Price History:
The Beta on a monthly basis for SMMT is -1.03, which has changed by 0.9866667 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, SMMT has reached a high of $36.91, while it has fallen to a 52-week low of $11.76. The 50-Day Moving Average of the stock is -6.59%, while the 200-Day Moving Average is calculated to be 8.39%.
Shares Statistics:
For the past three months, SMMT has traded an average of 3.99M shares per day and 3147020 over the past ten days. A total of 742.81M shares are outstanding, with a floating share count of 112.12M. Insiders hold about 84.90% of the company’s shares, while institutions hold 13.28% stake in the company. Shares short for SMMT as of 1755216000 were 29812741 with a Short Ratio of 7.48, compared to 1752537600 on 28557957. Therefore, it implies a Short% of Shares Outstanding of 29812741 and a Short% of Float of 25.52.
Earnings Estimates
The stock of Summit Therapeutics Inc (SMMT) is currently drawing attention from 8.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.07 and low estimates of -$0.57.
Analysts are recommending an EPS of between $0.08 and -$1.75 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is -$0.73, with 7.0 analysts recommending between -$0.29 and -$2.54.
Revenue Estimates
Based on 12 analysts’ estimates, the company’s revenue will be $1.54M in the next fiscal year. The high estimate is $42.85M and the low estimate is -$42.09M.
